OpenAI CEO Sam Altman stated that AI diagnostic tools have achieved accuracy levels superior to many human doctors. Altman pointed to AI’s potential to improve decision-making in drug development and clinical practice by providing unbiased, data-driven recommendations without personal career biases. Pharma firms like Sanofi are already integrating AI into drug development gating decisions. The remarks emphasize AI’s transformative impact on healthcare innovation and clinical workflows.